Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-22
2007-05-22
Solola, Taofiq (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S370100
Reexamination Certificate
active
10657033
ABSTRACT:
This invention relates to pyrazole derivatives of formula (I)or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1to R4are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
REFERENCES:
patent: 6586430 (2003-07-01), Armour
patent: 0223234.6 (2003-06-01), None
patent: WO 91/11172 (1991-08-01), None
patent: WO 94/02518 (1994-02-01), None
patent: WO 98/55148 (1998-12-01), None
patent: WO 02/04424 (2002-01-01), None
patent: WO 02/30907 (2002-04-01), None
patent: WO 02/085860 (2002-10-01), None
Stanovnic, et al., Science of Synthesis, 2002, 15-225, vol. 12.
Berge, et al., “Pharmaceutical Salts,”Journal of Pharmaceutical Sciences, 1977, 1-19, vol. 66, No. 1.
Bighley, et al., “Salt Forms of Drugs and Absorption,”Encyclopedia of Pharmaceutical Technology, Marcel Dekker Inc. New York, 1996, pp. 453-497, vol. 13.
Bundgaard, H.,Design of Prodrugs, 1985, Elsevier Science Publishers, Amsterdam, New York, Oxford.
Carey, et al., “Part A: Structure and Mechanisms,”Advanced Organic Chemistry, 3rdEdition, Plenum Press, New York, London, 1990.
Ferres, et. al. “Pro-Drugs ov β-Lactam Antibiotics,”Drugs of Today1983, 499-538, vol. 19, No. 9.
Genin, M. et al., “Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity Versus The Delavirdine-Resistant P236L Mutant: Lead Identification and SAR of 3- and 4-Substituted Derivatives,”Journal of Medicinal Chemestry, 2000, vol. 43, p. 1034-1040.
Greene, T.Protective Groups in Organic Synthesis 2ndEdition1991, John Wiley & Sons, Inc., New York, Chichester, Brisbane, Toronto, Singapore.
Hajimorad, et al., “Some Observations On The Binding Properties Of Alfalfa Mosaic Virus To Polystyrene And Its Significance To Indirect ELISA,”Archives of Virology, 1991, pp. 219-235, vol. 117.
Katritzky, et al. “The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds,”Comprehensive Heterocyclic Chemistryvol. 1-11, Pergamon Press, Oxford, New York, Toronto, Sydney, Paris, Frankfurt, 1984.
Edwards Paul John
Jones Lyn Howard
Mowbray Charles Eric
Stupple Paul Anthony
Tran Isabelle
Hutchinson Keith D.
Pfizer Inc.
Solola Taofiq
Zielinski Bryan C.
LandOfFree
Pyrazole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3793674